These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 15300157)

  • 1. Counteracting the sympathetic nervous system in essential hypertension.
    Grassi G
    Curr Opin Nephrol Hypertens; 2004 Sep; 13(5):513-9. PubMed ID: 15300157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihypertensive drugs and sympathetic nervous system.
    Rabbia F; Martini G; Cat Genova G; Milan A; Chiandussi L; Veglio F
    Clin Exp Hypertens; 2001; 23(1-2):101-11. PubMed ID: 11270578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Beta-Blockers in the Treatment of Hypertension.
    Cruickshank JM
    Adv Exp Med Biol; 2017; 956():149-166. PubMed ID: 27957711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of antihypertensive therapies on the sympathetic nervous system.
    de Champlain J; Karas M; Toal C; Nadeau R; Larochelle P
    Can J Cardiol; 1999 Mar; 15 Suppl A():8A-14A. PubMed ID: 10205251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sympathetic and baroreflex function in hypertension: implications for current and new drugs.
    Grassi G
    Curr Pharm Des; 2004; 10(29):3579-89. PubMed ID: 15579055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased sympathetic nervous system activity and its therapeutic reduction in arterial hypertension, portal hypertension and heart failure.
    Esler M; Kaye D
    J Auton Nerv Syst; 1998 Oct; 72(2-3):210-9. PubMed ID: 9851571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New drugs for the treatment of hypertension.
    Mancia G; Stella ML; Grassi G
    Curr Opin Cardiol; 1999 Sep; 14(5):375-80. PubMed ID: 10500899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure.
    Brooks DP; Ruffolo RR
    J Hypertens Suppl; 1999 Jun; 17(2):S27-32. PubMed ID: 10465064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the sympathetic nervous system in human hypertension.
    Grassi G
    J Hypertens; 1998 Dec; 16(12 Pt 2):1979-87. PubMed ID: 9886886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High blood pressure management: potential benefits of I1 agents.
    Esler M
    J Hypertens Suppl; 1998 Aug; 16(3):S19-24. PubMed ID: 9747906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart rate, sympathetic cardiovascular influences, and the metabolic syndrome.
    Grassi G; Arenare F; Quarti-Trevano F; Seravalle G; Mancia G
    Prog Cardiovasc Dis; 2009; 52(1):31-7. PubMed ID: 19615491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and trends in the drug treatment of essential hypertension.
    van Zwieten PA
    J Hypertens Suppl; 1992 Dec; 10(7):S1-12. PubMed ID: 1363322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sympathomodulatory Effects of Antihypertensive Drug Treatment.
    Grassi G
    Am J Hypertens; 2016 Jun; 29(6):665-75. PubMed ID: 26888777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Sympathetic nervous factors, pressure variability and organ damage in arterial hypertension].
    Mancia G; Seravalle G; Grassi G
    Ann Ital Med Int; 1997; 12(4):217-22. PubMed ID: 9773576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac effects of combination therapy in hypertension.
    Messerli FH; Chander K
    J Cardiovasc Pharmacol; 2000; 35 Suppl 3():S17-22. PubMed ID: 10854047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of chronic angiotensin converting enzyme inhibition on sympathetic nerve traffic and baroreflex control of the circulation in essential hypertension.
    Grassi G; Turri C; Dell'Oro R; Stella ML; Bolla GB; Mancia G
    J Hypertens; 1998 Dec; 16(12 Pt 1):1789-96. PubMed ID: 9869013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Insulin resistance and arterial hypertension].
    Weidmann P; Müller-Wieland D; de Courten M; Krone W
    Herz; 1995 Feb; 20(1):16-32. PubMed ID: 7713473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there a rationale for angiotensin blockade in the management of obesity hypertension?
    Sharma AM
    Hypertension; 2004 Jul; 44(1):12-9. PubMed ID: 15173127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal protection in hypertensive patients: selection of antihypertensive therapy.
    Wenzel RR
    Drugs; 2005; 65 Suppl 2():29-39. PubMed ID: 16398060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HYT-hypertension in Turkey: a cross-sectional survey on blood pressure control with calcium channel blockers alone or combined with other antihypertensive drugs.
    Seravalle G; Koylan N; Nalbantgil I; Caglar N; Quarti-Trevano F; Makel W; Grassi G; Fici F
    High Blood Press Cardiovasc Prev; 2015 Jun; 22(2):165-72. PubMed ID: 25900022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.